A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma-Reference-Cited by-同舟云学术

A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma

Published:1989-04 Issue:4 Volume:28 Page:
ISSN:0340-7004
Container-title:Cancer Immunology Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Lindemann Albrecht,H�ffken Klaus,Schmidt ReinholdE.,Diehl Volker,Kloke Otto,Gamm Heinold,Hayungs J�rg,Oster Wolfgang,B�hm Markus,Kolitz JonathanE.,Franks ChrisR.,Herrmann Friedhelm,Mertelsmann RolandH.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/BF00205237.pdf

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of High Dose Interleukin-2 in the Era of Targeted Therapy;Journal of Urology;2017-09

2. Clinical Response Rates From Interleukin-2 Therapy for Metastatic Melanoma Over 30 Years’ Experience: A Meta-Analysis of 3312 Patients;Journal of Immunotherapy;2017-01

3. A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors;BMC Cancer;2013-01-15

4. Outpatient Intravenous Interleukin-2 with Famotidine Has Activity in Metastatic Melanoma;Cancer Biotherapy and Radiopharmaceuticals;2012-09

5. Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial;Cancer Immunology, Immunotherapy;2012-03-20